China National Center for Cardiovascular Diseases

8 marketed · 1 in Phase 3

Quick facts

Marketed products

Aspirin + Clopidogrel + Rivaroxaban · Cardiovascular
This triple anticoagulant/antiplatelet combination inhibits blood clotting through multiple pathways: aspirin and clopidogrel block platelet aggregation, while rivaroxaban inhibits Factor Xa in the coagulation cascade.
De-escalated Dual Antiplatelet Therapy · Cardiovascular
De-escalated dual antiplatelet therapy reduces the duration or intensity of combined antiplatelet treatment to minimize bleeding risk while maintaining thrombotic protection.
low-dose rivaroxaban · Cardiovascular
Low-dose rivaroxaban selectively inhibits Factor Xa in the coagulation cascade, reducing thrombin generation and blood clot formation at a lower dose than standard anticoagulation.
Oral anticoagulation therapy · Cardiovascular
Oral anticoagulation therapy prevents blood clot formation by inhibiting coagulation cascade factors, reducing thromboembolism risk.
Qishen Yiqi Drop Pills
Single antiplatelet therapy · Cardiovascular
Single antiplatelet therapy inhibits platelet aggregation to reduce thrombotic events in cardiovascular disease.
Standard-dose rivaroxaban
Torsemide Tablets · Cardiovascular
Torsemide is a loop diuretic that inhibits sodium and chloride reabsorption in the ascending limb of the loop of Henle, promoting urinary excretion of water and electrolytes.

Phase 3 pipeline

Intensive BP treatment group · Cardiovascular
This is a treatment strategy that uses intensive blood pressure control to reduce cardiovascular events and mortality in hypertensive patients.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about China National Center for Cardiovascular Diseases

What are China National Center for Cardiovascular Diseases's marketed drugs?

Top marketed products include Aspirin + Clopidogrel + Rivaroxaban, De-escalated Dual Antiplatelet Therapy, low-dose rivaroxaban, Oral anticoagulation therapy, Qishen Yiqi Drop Pills, Single antiplatelet therapy.

What is China National Center for Cardiovascular Diseases's pipeline?

China National Center for Cardiovascular Diseases has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Intensive BP treatment group.

Aspirin + Clopidogrel + Rivaroxaban · Cardiovascular
De-escalated Dual Antiplatelet Therapy · Cardiovascular
low-dose rivaroxaban · Cardiovascular
Oral anticoagulation therapy · Cardiovascular
Qishen Yiqi Drop Pills
Sector hub: All tracked pharma companies